Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Net Cash Flow (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Net Cash Flow data on record, last reported at -$3.7 million in Q3 2025.

  • For Q3 2025, Net Cash Flow fell 106.47% year-over-year to -$3.7 million; the TTM value through Sep 2025 reached -$48.9 million, down 182.28%, while the annual FY2024 figure was -$3.4 million, 166.93% down from the prior year.
  • Net Cash Flow reached -$3.7 million in Q3 2025 per CAPR's latest filing, up from -$5.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $57.7 million in Q3 2024 and bottomed at -$57.1 million in Q4 2024.
  • Average Net Cash Flow over 5 years is -$692394.3, with a median of -$768395.0 recorded in 2023.
  • The widest YoY moves for Net Cash Flow: up 6867.31% in 2024, down 1099.8% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$6.0 million in 2021, then surged by 119.98% to $1.2 million in 2022, then skyrocketed by 380.01% to $5.7 million in 2023, then plummeted by 1099.8% to -$57.1 million in 2024, then skyrocketed by 93.47% to -$3.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$3.7 million in Q3 2025, -$5.6 million in Q2 2025, and $17.5 million in Q1 2025.